

Transaction in the healthcare sector: Walther Transaction advised on the acquisition of Uniqsana by Darwin

Munich, 06/02/2023 - The M&A consultancy Walther Transaction advised Darwin AG based in Munich in its search for a suitable acquisition target and was able to find a fitting partner in Uniqsana GmbH & Co. KG, based in Heilbronn, Germany. The transaction was closed on September 22, 2022. Darwin acquired a minority stake in Uniqsana.

Darwin is one of the leading biotechnology companies in Europe and is active in the field of preventive and lifestyle genetic testing, as well as individualized nutritional supplements and cosmetics. Walther Transaction worked in a longer-term partnership with Darwin with the objective to identify and qualify suitable acquisition targets in complementary areas such as laboratory services, personalized nutritional supplements and cosmetics.

After intense discussion of the target criteria with Darwin, extensive market research and confidential approach of all relevant target companies, Walther Transaction identified Uniqsana as a fitting strategic partner. Uniqsana is a state-of-the-art clean room laboratory for the in-house production of individual pharmaceuticals.

Mark Walther, Managing Partner of Walther Transaction, expressed his satisfaction with the successful transaction: "Uniqsana's portfolio perfectly complements Darwin's and helps in the further development of personalized products. We wish both companies a successful future together!"

About Darwin AG:

DARWIN (formerly Novogenia Holding AG), headquartered in Munich and listed on the stock exchange there, is one of Europe's leading biotechnology companies in the field of human genetics. The genetic analyses carried out in the company's own laboratory are used in the diagnosis, therapy and prevention of diseases as well as in the production of individually designed food supplements and cosmetics. Darwin acts as a partner for doctors, therapists, pharmacists, nutritionists or fitness trainers and helps to ensure the best possible treatment or care for the patient's or customer's needs by analyzing their genetic predisposition.

About Uniqsana GmbH & Co. KG:

Uniqsana is at the forefront of small-format drug development for an international market. The company's sterile pharmaceutical-grade laboratory and certifications allow medical professionals to produce personalized infusions with ingredients in drug dosages for their patients. Uniqsana operates internationally.

About Walther Transaction GmbH:

Walther Transaction GmbH is an internationally active transaction specialist for company sales and company acquisitions based in Munich. So far, the teams led by Mark Walther and Moneshia zu Eltz have successfully completed over 350 corporate transactions and business development projects, out of which more than 100 are buy-side transactions. Walther Transaction has expertise particularly in the sectors healthcare and technology.

Press contact:

Walther|Transaction.

Karin Olliges

Wehrlestraße 13, G-81679 Munich

P: +49 89 230 2141 10

E: olliges@walther-transaction.com